1. Generics Bulletin
  2. >>Products
  3. >>Generics

Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle

 
• By Jessica Merrill

FDA cleared Mylan's generic version of Copaxone 40mg even after management warned investors not to expect action until 2018. Mylan said it will launch "imminently, but Teva said a launch ahead of the pending appeals case would be "at risk."

FDA approved background, 3D rendering, blue street sign

Mylan NV has won FDA approval of the first generic version of a 40mg dose of Teva Pharmaceutical Industries Ltd.'s Copaxone (glatiramer) for multiple sclerosis, setting Mylan up for a potentially lucrative commercial opportunity while adding to Teva's mounting challenges.

The news, announced after market close Oct. 3, took investors from both companies by surprise since Mylan's management recently warned...

More from Generics

More from Products